Basit öğe kaydını göster

First-line pembrolizumab in advanced urothelial carcinoma: Clinical parameters associated with efficacy in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-361 trials.

dc.contributor.authorHahn, Noah M.
dc.contributor.authorCsoszi, Tibor
dc.contributor.authorPowles, Thomas
dc.contributor.authorAlva, Ajjai Shivaram
dc.contributor.authorCastellano, Daniel E.
dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorO'Donnell, Peter H.
dc.contributor.authorLoriot, Yohann
dc.contributor.authorFlechon, Aude
dc.contributor.authorRodriguez-Vida, Alejo
dc.contributor.authorDe Wit, Ronald
dc.contributor.authorCheng, Susanna Y.
dc.contributor.authorOudard, Stephane
dc.contributor.authorVulsteke, Christof
dc.contributor.authorYu, Evan Y.
dc.contributor.authorLin, Jianxin
dc.contributor.authorImai, Kentaro
dc.contributor.authorMoreno, Blanca Homet
dc.contributor.authorBalar, Arjun Vasant
dc.contributor.authorGrivas, Petros
dc.date.accessioned2022-07-04T16:22:11Z
dc.date.available2022-07-04T16:22:11Z
dc.date.issued2022
dc.identifier.citationCsoszi T., Powles T., Alva A. S. , Castellano D. E. , Ozguroglu M., O'Donnell P. H. , Loriot Y., Hahn N. M. , Flechon A., Rodriguez-Vida A., et al., "First-line pembrolizumab in advanced urothelial carcinoma: Clinical parameters associated with efficacy in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-361 trials.", JOURNAL OF CLINICAL ONCOLOGY, cilt.40, sa.6, 2022
dc.identifier.issn0732-183X
dc.identifier.otherav_e1a3a425-2bc3-4cc8-ae04-040342655597
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/185061
dc.identifier.urihttps://doi.org/10.1200/jco.2022.40.6_suppl.521
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectOncology
dc.subjectHealth Sciences
dc.titleFirst-line pembrolizumab in advanced urothelial carcinoma: Clinical parameters associated with efficacy in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-361 trials.
dc.typeMakale
dc.relation.journalJOURNAL OF CLINICAL ONCOLOGY
dc.contributor.department, ,
dc.identifier.volume40
dc.identifier.issue6
dc.contributor.firstauthorID3405580


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster